Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:RUBY

Rubius Therapeutics (RUBY) Stock Price, News & Analysis

Rubius Therapeutics logo

About Rubius Therapeutics Stock (NASDAQ:RUBY)

Key Stats

Today's Range
$0.06
$0.06
50-Day Range
$0.02
$0.06
52-Week Range
$0.00
$0.38
Volume
755,858 shs
Average Volume
1.15 million shs
Market Capitalization
$5.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Stock News Headlines

How to Get the Exclusive Rubius Fortnite Drop
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
Rubius Therapeutics Inc RUBY
RUBY - Rubius Therapeutics, Inc.
North American Morning Briefing: Alphabet, -2-
See More Headlines

RUBY Stock Analysis - Frequently Asked Questions

Rubius Therapeutics, Inc. (NASDAQ:RUBY) released its earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.01.

Rubius Therapeutics (RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rubius Therapeutics investors own include Meta Platforms (META), Sorrento Therapeutics (SRNE), Pfizer (PFE), Bristol-Myers Squibb (BMY), OPKO Health (OPK), Tesla (TSLA) and Athenex (ATNX).

Company Calendar

Last Earnings
11/08/2021
Today
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RUBY
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.17 per share

Miscellaneous

Free Float
85,687,000
Market Cap
$5.16 million
Optionable
Not Optionable
Beta
2.59
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:RUBY) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners